Feasibility Study: Ulthera System for the Treatment of Rosacea

NCT ID: NCT01756027

Last Updated: 2017-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-30
• Study Completion Date: 2013-10-31

Brief Summary

Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment. Study images will be obtained pre-treatment, 30-60 min post-treatment, and at each follow-up visit.

Detailed Description

This study is a prospective, randomized, single-center clinical trial. The study will be conducted in two Phases. In Phase I, subjects will be assigned to one of two treatment groups. One study group will receive one dual depth Ultherapy treatment to a region on the cheeks, and one study group will receive two dual depth Ultherapy treatments to a region on the cheeks 14 days apart. Average pain scores will be obtained using a Numeric Rating Scale following each region of treatment and for each depth of treatment. In Phase II, based on observations of last follow-up visit in Phase I (at 90 days after treatment), subjects will be given the option to receive treatment of the affected area(s) for the protocol specified region, treated at the treatment depth showing the most efficacy in Phase I. Efficacy will be determined by improvement in Erythematotelangiectatic Rosacea in the treatment area versus control (an untreated area) as determined by primary investigator assessment at the last follow-up visit in Phase I.

Conditions

Erythematotelangiectatic Rosacea

Keywords

Rosacea; Ulthera System; Ultherapy™ Treatment; Ulthera, Inc.; Ultrasound treatment for the skin

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A

Ulthera System providing one treatment per cheek

Group Type: ACTIVE_COMPARATOR

Ulthera System providing one treatment per cheek

Intervention Type: DEVICE

Focused ultrasound energy delivered below the surface of the skin per cheek.

Group B

Ulthera System providing two treatments per cheek

Group Type: ACTIVE_COMPARATOR

Ulthera System providing two treatments per cheek

Intervention Type: DEVICE

Focused ultrasound energy delivered below the surface of the skin

Interventions

Ulthera System providing one treatment per cheek

Focused ultrasound energy delivered below the surface of the skin per cheek.

Intervention Type: DEVICE

Ulthera System providing two treatments per cheek

Focused ultrasound energy delivered below the surface of the skin

Intervention Type: DEVICE

Other Intervention Names

Ultherapy™; Ultherapy™

Eligibility Criteria

Inclusion Criteria

• Male or female, aged 18 to 65 years.
• Subject in good health.
• Clinical diagnosis of Erythematotelangiectatic Rosacea.
• Understands and accepts the obligation not to undergo any other procedures in the area(s) to be treated through the follow-up period.
• Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
• Absence of physical or psychological conditions unacceptable to the investigator.
• Willingness and ability to provide written consent for study-required photography and adherence to photography requirements.
• Willingness and ability to provide written informed consent and HIPAA authorization prior to performance of any study-related procedure.
• Subjects of childbearing potential must have a negative urine pregnancy test result and must not be lactating at Visit 1.

Exclusion Criteria

• Presence of an active systemic disease that may affect wound healing.
• Prominent telangiectases in the area(s) to be treated.
• History of post-inflammatory hyperpigmentation.
• Papulopustular or Phymatous Rosacea.
• Severe solar elastosis.
• Significant scarring in area(s) to be treated.
• Open wounds or lesions in the area(s) to be treated.
• Severe or cystic acne on the area(s) to be treated.
• Presence of a metal stent or implant in the area(s) to be treated.
• Inability to understand the protocol or to give informed consent.
• Microdermabrasion, or prescription level glycolic acid treatments to the intended treatment area(s) within six weeks prior to study participation or during the study.
• Marked asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin in the area(s) to be treated.
• History of chronic drug or alcohol abuse.
• History of autoimmune disease.
• Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study device.
• Subjects who anticipate the need for surgery or overnight hospitalization during the study.
• Subjects who, in the investigator's opinion, have a history of poor cooperation,noncompliance with medical treatment, or unreliability.
• Concurrent enrollment in any study involving the use of investigational devices or drugs.
• Current smoker or history of smoking in the last five years.
• History of the following cosmetic treatments in the area(s) to be treated:

1. Skin tightening procedure within the past year;

2. Injectable filler of any type within the past:

• 12 months for Hyaluronic acid fillers (e.g.,Restylane)
• 12 months for Ca Hydroxyapatite fillers (e.g., Radiesse)
• 24 months for Poly-L-Lactic acid fillers (e.g., Sculptra)
• Ever for permanent fillers (e.g., Silicone, ArteFill)

3. Neurotoxins within the past three months;

4. Ablative resurfacing laser treatment;

5. Nonablative, rejuvenative laser or light treatment within the past six months;

6. Surgical dermabrasion or deep facial peels

• History of using the following prescription medications:

1. Accutane or other systemic retinoids within the past six months;

2. Topical Retinoids within the past two weeks;

3. Antiplatelet agents / Anticoagulants (Coumadin, Heparin, Plavix);

4. Psychiatric drugs that in the investigators opinion would impair the subject from understanding the protocol requirements or understanding and signing informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ulthera, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark Lupin, M.D.

Role: PRINCIPAL_INVESTIGATOR

Cosmedica

Locations

Cosmedica

Victoria, British Columbia, Canada

Countries

Canada

Other Identifiers

ULT-131

Identifier Type: -

Identifier Source: org_study_id